Movement Alert｜JOINN Rises 5.24% in Regular Trading, CXO Sector Strength Continues to Lift Pre-Clinical CRO Leader

Market Focus08-10

On August 10, JOINN rose 5.24% in regular trading, trading at HK$28.7/share, with turnover of HK$140 million. The gain was primarily driven by continued strength across the Life Sciences Tools and Services sector.

On the news front, the CXO sector extended its rally with WuXi AppTec up 3.85%, WuXi Biologics up 4.58%, and GenScript Biotech up 4.96%. The sector-wide momentum was fueled by WuXi AppTec's disclosed half-year results showing revenue of RMB 28.897 billion, up 38.93% year-over-year, with adjusted net profit surging 89.39%, alongside a full-year guidance upgrade that continues to bolster CXO sector sentiment.

Additionally, JOINN itself recently issued a strong half-year earnings forecast, projecting attributable net profit of RMB 600 million to RMB 900 million, representing growth of 885% to 1,377% year-over-year, primarily driven by biological asset fair value gains of RMB 703 million to RMB 777 million.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1186956734?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-10 09:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1186956734","market":"us","top_or_hot":-1,"title":"Movement Alert｜JOINN Rises 5.24% in Regular Trading, CXO Sector Strength Continues to Lift Pre-Clinical CRO Leader","media":"Market Focus","content":"<p><p>On August 10, JOINN rose 5.24% in regular trading, trading at HK$28.7/share, with turnover of HK$140 million. The gain was primarily driven by continued strength across the Life Sciences Tools and Services sector.</p><p>On the news front, the CXO sector extended its rally with WuXi AppTec up 3.85%, WuXi Biologics up 4.58%, and GenScript Biotech up 4.96%. The sector-wide momentum was fueled by WuXi AppTec's disclosed half-year results showing revenue of RMB 28.897 billion, up 38.93% year-over-year, with adjusted net profit surging 89.39%, alongside a full-year guidance upgrade that continues to bolster CXO sector sentiment.</p><p>Additionally, JOINN itself recently issued a strong half-year earnings forecast, projecting attributable net profit of RMB 600 million to RMB 900 million, representing growth of 885% to 1,377% year-over-year, primarily driven by biological asset fair value gains of RMB 703 million to RMB 777 million.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜JOINN Rises 5.24% in Regular Trading, CXO Sector Strength Continues to Lift Pre-Clinical CRO Leader</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜JOINN Rises 5.24% in Regular Trading, CXO Sector Strength Continues to Lift Pre-Clinical CRO Leader\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-08-10 09:48</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On August 10, JOINN rose 5.24% in regular trading, trading at HK$28.7/share, with turnover of HK$140 million. The gain was primarily driven by continued strength across the Life Sciences Tools and Services sector.</p><p>On the news front, the CXO sector extended its rally with WuXi AppTec up 3.85%, WuXi Biologics up 4.58%, and GenScript Biotech up 4.96%. The sector-wide momentum was fueled by WuXi AppTec's disclosed half-year results showing revenue of RMB 28.897 billion, up 38.93% year-over-year, with adjusted net profit surging 89.39%, alongside a full-year guidance upgrade that continues to bolster CXO sector sentiment.</p><p>Additionally, JOINN itself recently issued a strong half-year earnings forecast, projecting attributable net profit of RMB 600 million to RMB 900 million, representing growth of 885% to 1,377% year-over-year, primarily driven by biological asset fair value gains of RMB 703 million to RMB 777 million.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06127","symbol_name":"昭衍新药","start_time":0,"source_url":"","article_id":"1186956734","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1186956734","pubTimestamp":1786326480,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On August 10, JOINN rose 5.24% in regular trading, trading at HK$28.7/share, with turnover of HK$140 million. The gain was primarily driven by continued strength across the Life Sciences Tools and...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06127":"昭衍新药"},"translate_title":"走势警报|JOINN 常规交易上涨 5.24%，CXO 板块实力继续提升临床前 CRO 领导者","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06127":1},"content_text":"On August 10, JOINN rose 5.24% in regular trading, trading at HK$28.7/share, with turnover of HK$140 million. The gain was primarily driven by continued strength across the Life Sciences Tools and Services sector.On the news front, the CXO sector extended its rally with WuXi AppTec up 3.85%, WuXi Biologics up 4.58%, and GenScript Biotech up 4.96%. The sector-wide momentum was fueled by WuXi AppTec's disclosed half-year results showing revenue of RMB 28.897 billion, up 38.93% year-over-year, with adjusted net profit surging 89.39%, alongside a full-year guidance upgrade that continues to bolster CXO sector sentiment.Additionally, JOINN itself recently issued a strong half-year earnings forecast, projecting attributable net profit of RMB 600 million to RMB 900 million, representing growth of 885% to 1,377% year-over-year, primarily driven by biological asset fair value gains of RMB 703 million to RMB 777 million.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1186956734","isCrawlerRequest":true}